🟢 Outlook Therapeutics is trading 10.72% up today following July 24 FDA approval of LYTENAVA

Outlook Therapeutics is trading at $1.13, up +10.72%, following the July 24 FDA approval of LYTENAVA for wet AMD.

• LYTENAVA became the first FDA-approved ophthalmic bevacizumab formulation in the United States.
• No new company-specific announcement dated August 10, 2026 was identified.
• The advance appears primarily technical and sentiment-driven; broader market performance was mixed.